Septerna (NASDAQ:SEPN) Price Target Raised to $60.00

Septerna (NASDAQ:SEPN) had its price target raised by Stifel Nicolaus from $49.00 to $60.00 in a report published on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other analysts have also weighed in on SEPN. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Wells Fargo & Company increased their price objective on shares of Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. raised their price objective on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. JonesTrading boosted their target price on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Septerna has an average rating of “Moderate Buy” and an average target price of $56.44.

Septerna Stock Down 13.8%

SEPN stock opened at $41.86 on Tuesday. The company has a market capitalization of $1.99 billion, a P/E ratio of -32.45 and a beta of 2.20. The company has a 50-day simple moving average of $40.35 and a 200 day simple moving average of $33.03. Septerna has a fifty-two week low of $18.64 and a fifty-two week high of $53.34.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15). The company had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. Equities analysts anticipate that Septerna will post -1.47 EPS for the current year.

Insider Transactions at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $6,517,158.69. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Daniel Long sold 3,333 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at approximately $3,647,265.96. This trade represents a 3.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Septerna

Several hedge funds have recently made changes to their positions in SEPN. TRV GP V LLC bought a new stake in shares of Septerna in the 2nd quarter worth approximately $208,160,143. TRV GP VI LLC bought a new stake in Septerna during the second quarter worth approximately $141,048,460. BlackRock Inc. acquired a new position in Septerna in the second quarter worth approximately $64,706,000. Jupiter Topco LLC acquired a new position in Septerna in the second quarter worth approximately $43,723,000. Finally, Primecap Management Co. CA acquired a new position in Septerna in the second quarter worth approximately $39,096,000.

Septerna News Summary

Here’s some of the latest news about SEPN:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $60 target, while raising its FY2027 EPS estimate to a loss of $1.34 per share from $1.41. It also improved estimates for several 2027 quarters, suggesting a better projected earnings trajectory later on.
• Positive Sentiment: A recent analyst upgrade coincided with SEPN reaching a new 52-week high, reflecting momentum and favorable investor interest. Septerna Reaches New 52-Week High Following Analyst Upgrade
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $1.48 per share from $1.15, and reduced estimates for Q4 2026 and Q1 2027. These near-term downgrades temper the more favorable 2027 revisions.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.